gdc
Cervical Cancer

Drugs for Cervical Cancer

Here are the drugs and financial support services available to patients receiving treatment for Cervical Cancer.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Card

Patients with private insurance pay a $5 copay, and up to $25,000 is paid by the program annually; there are no income requirements for participation.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Avastin is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Hycamtin (topotecan hydrochloride injection)

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used, in combination with cisplatin, for the treatment of patients with stage IV-B, recurrent or persistent carcinoma of the cervix.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Hycamtin for free for 1 year, or until prescription drug coverage becomes available to them.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $60,700 or less for individuals, $82,300 or less for a couple, or $125,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab)
  • Drug company
  • Genentech
  • Indication
  • Recurrent, persistent, or metastatic cervical cancer, in combination with paclitaxel and
    cisplatin or paclitaxel and topotecan
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Hycamtin (topotecan hydrochloride injection)
  • Drug company
  • Novartis
  • Indication
  • Stage IV-B, recurrent or persistent carcinoma of the cervix, in combination with cisplatin
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of recurrent or metastatic cervical cancer progressing during or after chemo­therapy in patients whose tumors express PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

Last modified: March 7, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country